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ABSTRACT
The aim of present investigation was to develop a taste masked 
fast dissolving sublingual strips of rizatriptan benzoate. The 
fast dissolving strips (FDS) were prepared by solvent casting 
method using polyox N-10 and polyethylene glycol 400 (PEG 
400) as polymer and plasticizer respectively. The FDS were 
evaluated for pH, folding endurance, tensile strength, moisture 
absorption, disintegration time and in vitro dissolution. All 
formulations were free from bubble and exhibited smooth 
appearance. The pH of the films was acidic. It was observed 
that increase in the concentration of polyox N-10 increased 
the disintegration time but reduced the dissolution rate. 
The formulation A2 showed all the evaluation parameters 
within the acceptable range and was considered as optimized 
formulation. The optimized formulation was subjected to the 
taste masking and stability study. The results of taste masking 
study indicated an efficient masking of the bitter taste of drug 
by the flavouring agents in the film. The formulation A2 was 
found to be stable for three months with an insignificant 
change in the drug content and mean dissolution time (MDT). 
The compatibility study performed using ATR-FTIR and 
DSC analysis indicated absence of any unusual interaction 
between drug and excipients used in formulation. Thus, the 
FDS comprised of polyox N-10 and PEG 400 may be a better 
alternative to the other available fast dissolving systems for 
delivery of rizatriptan benzoate.
Keywords: Fast dissolving strips, Polyox N-10, PEG 400, 
Rizatriptan benzoate
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1. INTRODUCTION
Migraine is a severe neurological disorder which affects 
around 12% of the worldwide population. It can cause severe 
throbbing pain or pulsing sensation on one side of the head. 
In some patients, a migraine attack may cause nausea and 
vomiting (1). In the United States, more than 28% people are 
suffering from migraine headache(2). The triptans and non-
steroidal anti-inflammatory drugs have been found to provide 
a symptomatic relief in migraine (3). Rizatriptan benzoate 
is a selective 5-hydroxytriptamine (5-HT) 1B/1D receptor 
agonist which is used for the acute treatment of migraine in 
adults with or without aura(4). Although it is a cost effective 
oral triptan available for the treatment of migraine, it suffers 
from some drawbacks such as poor oral bioavailability due to 
an extensive first-pass effect and the bitter taste (5). Due to 
this reason, rizatriptan benzoate is available in the market as 
an orodispersible tablet.
Orodispersible tablets (ODTs) may prevent the hepatic and 
gut-wall first pass metabolism by allowing the drug to be 
absorbed from the upper GI tract into the systemic circulation. 
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Besides, the ODTs may avoid choking during administration 
and the flavoring agents used in these tablets may mask the 
unpleasant taste of the bitter drug. This may help to improve 
the patient compliance (6). Nonetheless, these tablets also 
suffer from some drawbacks. The disintegrated materials 
from the ODTs usually remain undissolved until swallowed 
which may cause an unpleasant feeling in the oral cavity (7). 
On the other hand, problems related to the friability may 
arise during the handling, transportation, and storage of the 
ODTs due to their high porosity, low mechanical strength 
and low density (8). These drawbacks of the ODTs can be 
overcome using fast dissolving sublingual strips (FDSSs)(9).
Research and development in the oral drug delivery field has 
led to transition of dosage forms from simple conventional 
tablets/capsules to the development of oral thin strips(10). 
Based on technology of transdermal patch, oral strips were 
developed which consists of a very thin strip that can be 
placed on the patient’s tongue. The strip rapidly hydrates 
when it comes in contact with saliva and quickly absorbed 
in the systemic circulation. The strip offers advantages 
like convenience of dosing and portability that leads to its 
wider acceptability by pediatric as well as geriatric patients 
(11). The sublingual strips are now gaining the importance 
in the treatment of migraine as it helps to avoid the first 
pass metabolism of the drug and promotes rapid onset of 
pharmacological action (1).
Many coworkers have prepared thin oral film by using natural 
polymers such as pullulan, xanthan(12), and synthetic 
polymers like hydroxypropylmethylcellulose(13), polyvinyl 
pyrrolidone(14), etc(15). Polyox N-10 is a well known film 
forming polymer widely used as a binding agent for tablets, 
granules, pellets, etc. The film forming ability of the polymer 
depends on its nature and concentration (16).
Considering the above facts, the present investigation aims to 
formulate taste masked FDDS of rizatriptan benzoate using 
polyox N-10 (film forming agent) for migraine therapy and 
to study the effect of formulation variables on the properties 
of FDSSs.
2. MATERIALS AND METHODS
2.1 Materials
Rizatriptan benzoate was obtained as a gift sample from Cipla 
Ltd. Kurkumnbh, Pune, India. Polyox N-10 was gifted from 
Colorcon Asia Pvt. Ltd., Goa. Sucralose and strawberry flavor 
were received as a gift sample from Okasa Pharma, Satara. 
Polyethylene glycol 400 (PEG 400) and other analytical grade 
chemicals were purchased from Loba Chemie, Mumbai, 
India.
2.2 Preparation of oral fast dissolving strips of Rizatriptan 
benzoate
The fast dissolving strips of rizatriptan benzoate were 
prepared by solvent casting method. In brief, PEG 400 
(plasticizer) and the polyox N-10 were dissolved in the water 
by stirring on magnetic stirrer (Remi, India). The stirring 
was continued for 4 h and the solution was kept aside for 
1 h to remove the entrapped air bubbles. Meanwhile, in 
the separate container, a solution of other water soluble 
ingredients such as sucralose and citric acid was prepared 
followed by addition of menthol, strawberry and Tween 
80 with constant stirring for 45 min. Both the solutions 
were mixed together and stirred for 1 h. The mixture was 
kept stationary to settle the foam. Finally, the mixture was 
casted on a suitable inert platform (44.15cm2) and dried to 
form thin film. The film was tested for any imperfections 
and strips were cut according to the size required (2.5 x 
2.5 cm)(11). The formulation codes and their respective 
compositions are given in table 1.
Table 1. Formulations of oral fast dissolving strips 
containing polyox N-10
Ingredients A1 A2 A3 A4 A5 A6 A7
Polyox N-10 4 6 8 10 12 6 6
PEG-400 4 4 4 4 4 2 6
Sucralose 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Citric acid 1 1 1 1 1 1 1
Menthol 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Strawberry 0.25 0.25 0.25 0.25 0.25 0.25 0.25
Tween 80 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Rizatriptan benzoate 5 5 5 5 5 5 5
Water q.s q.s q.s q.s q.s q.s q.s
All ingredients in % w/v
2.3 Weight of strips
Oral fast dissolving strips were weighed on analytical single 
pan balance (AX 120, Shimadzu, Japan) (17).
2.4 Thickness of strips
The thickness of strips was measured by using a micrometer 
screw gauge (10).
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2.5 Folding endurance of strips
Folding endurance of the strips was measured manually. A 
strip was repeatedly folded at the same place till it breaks. 
The number of times the strip could be folded at the same 
place without breaking gives the folding endurance of the 
strip (18). The folding endurance also gives an idea about 
brittleness of the film.
2.6 Tensile Strength of strips
Tensile strength is the maximum stress required to break the 
strip. In this test, the strip was tied between two clamps and 
one end of clamp was directly attached to pan through pulley. 
The strips were subjected to stress by adding load to the pan. 
The load was increased until the film breaks (failure). The 
minimum load required for breaking the film (load at failure) 
was noted (10). It is calculated by the following formula,
 widthStrip   thicknessStrip
100  failureat  Load strength  Tensile
×
×
=
 
(1)
2.7 pH of strips
The pH of the FDSSs was determined by dissolving each 
oral strip in 5ml distilled water and measuring the pH of the 
solution with the help of pH meter (Systronic, India) (19).
2.8 Moisture absorption study
Moisture absorption capacity of the strips was determined 
according to the previously reported method (17). The 
pre-weighed strips were placed in a desiccator at room 
temperature. After 72 h, the strips were removed from the 
desiccator and exposed to 75% relative humidity by using 
humidity chamber (Bio-Technics, India). The moisture 
uptake was measured as percent increase in the weight of the 
strip using following formula:
 weightInitial
 weightInitial - weight Final  absorption moisturePercent =
 
(2)
2.9 Content Uniformity
Drug content was determined by dissolving the strip 
containing 5 mg of drug in 100 ml phosphate buffer (pH 
6.4). An aliquot equivalent to 2 ml was suitably diluted 
and analyzed using UV- spectrophotometer (UV-1800, 
Shimadzu, Japan) at 225 nm. The measurements were done 
against blank solution prepared by using dummy strip treated 
in same manner.
2.10 Disintegration time of strips
The disintegration time of strips was determined by using 
disintegrating test apparatus (Electrolab, India). The 
disintegrating test was carried out in 900 ml phosphate 
buffer pH 6.4 at 37±0.50C (10). Time required to disintegrate 
the strip was recorded. The measurements were done in 
triplicate.
2.11 In Vitro Dissolution Studies
The in vitro dissolution study for the FDSSs and marketed 
ODT of rizatriptan benzoate was carried out in 900 ml 
phosphate buffer (pH 6.4) using USP dissolution type II 
apparatus at 37±0.5°C (stirring speed = 50 rpm). The strip 
was submerged into the dissolution media and appropriate 
aliquots were withdrawn at predetermined time intervals. 
The samples were analyzed spectrophotometrically (UV-
1800, Shimadzu, Japan) at 225 nm. Sink conditions were 
maintained throughout the experiment(10,17). The same 
procedure was repeated for the marketed ODT (Rizact-
5MD). The dissolution test was performed in triplicate.
2.12 Stability Studies
The strips were wrapped in aluminum foil and subjected to 
stability test at temperature 40o C with relative humidity of 
75% RH (Bio-Technics, India). The strips were withdrawn 
after 90 days and evaluated for weight, thickness, folding 
endurance, tensile strength, disintegration time, drug content 
and in vitro dissolution. The in vitro dissolution data of the 
optimized formulation before and after stability studies was 
compared using similarity factor, ƒ2. The formulation before 
stability studies was considered as reference formulation 
whereas formulation after stability studies was considered as 
test formulation (17). Dissolution profiles were considered as 
similar if ƒ2 value lied between 50-100(20).
2.13 Evaluation of Taste
In order to achieve patient compliance, taste masking is 
necessary for the fast dissolving systems containing bitter 
drug. Taste of the formulation A2 was evaluated by time 
intensity method using a panel of human volunteers (21). For 
this purpose, nine healthy human volunteers were selected 
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and strip was held in the volunteer’s mouth. Bitterness level 
was recorded immediately at 15, 30, 60, 90, and 120 seconds. 
Bitterness values were rated by giving different values as 
mentioned below:
00- Sweet; 0- Slightly sweet; 1-No bitterness and 2- Bitter
2.14 Compatibility study
The compatibility in between drug and formulation excipients 
was determined using attenuated total reflectance–fourier 
transform infrared (ATR-FTIR) spectroscopy and differential 
scanning calorimetry (DSC). An ATR-FTIR spectrum of 
rizatriptan benzoate and formulation was recorded by using 
ATR-FTIR (Alpha E, Bruker, Japan) Spectrophotometer. 
The samples to be analyzed were transferred to the ATR 
compartment. The spectra were obtained for the range of 
600-4000/cm at an average of 25 scans and resolution of 4/
cm. Differential scanning calorimetry (DSC) thermogram 
of the pure drug, physical mixture of pure drug and Polyox 
N-10 (1:1) and optimized strip formulation were recorded on 
a thermal analyzer (DSC 823e, Mettler Toledo, Melbourne, 
Australia). The samples were heated at the rate of 10°C/min 
in an inert nitrogen atmosphere. The heating was carried out 
in the temperature range of 30 to 300°C.
3. RESULTS AND DISCUSSION
3.1 Weight of strips
The average weight of respective formulations is given in 
table 2. The weight of strips was found to be in the range 
of 41±1.00mg to 74.3±1.52mg. The difference in the 
average weight of all formulations may be due to change in 
excipients, their nature and concentration. It was observed 
that weight of films increased with increase in the polymer 
concentration.
3.3 Thickness of strips
The thickness of strips was found to be in between 30mm to 
80mm (table 2). The thickness was measures at three different 
regions of the film. The low value of standard deviation 
indicates that the variation in the weight of the films did 
not affect the mass uniformity. An increase in the polymer 
concentration from 4 to 12%, increased the thickness of the 
FDSSs possibly due to increase in the polymer bulk.
3.4 Folding endurance of strips
The folding endurance of all prepared strips was found to 
be in the range of 37±3.51 to 209±2 (table 2). The folding 
endurance of FDSSs was found to be decrease with increase 
in the polymer concentration. The increase in the polymer 
concentration may reduce the flexibility of the strips leading 
to decrease in its folding endurance. An increase in the folding 
endurance associated with increase in the concentration of 
PEG 400 can be attributed to the interference of the PEG 
with the glass transition temperature of the polymer within 
the strip. Such interference of the plasticizer may decrease 
the melting point of the polymer and enhance its flexibility, 
thus increasing folding endurance of the strips(22).
3.5 Tensile strength of strips
The FDSSs exhibited the tensile strength in the range of 
138.8±3.8 to 340.8±1.4 Kg/cm2 (table 2). An increase in the 
concentration of PEG 400 reduced the tensile strength of the 
strips possibly due to decrease in the rigidity. The addition 
of plasticizer leads to the formation of a more porous and 
less dense polymer structure due to which, the strip breaks at 
lesser force(22).On the other hand, increase in the polymer 
concentration increased the tensile strength of the strips. 
This may be due to the formation of densely packed network 
of Polyox N-10 chains at higher concentration.
Table 2. Evaluation of oral fast dissolving strips of rizatriptan benzoate
Formulations Wt. of strips
(mg) (n = 3)
Thickness
(mm) (n = 3)
Folding Endurance
(n = 3)
Tensile strength
(kg/cm2) (n = 3)
A1 41±1.0 30±0.52 177±2.0 138.8±3.8
A2 45±1.0 33.3±0.5 157±3.21 186±3.2
A3 53.3±2.5 50.0±1.5 138±2.16 241.3±2.3
A4 61±2.0 70±1.0 109±3.3 283.5±1.8
A5 74.3±1.5 80±0.52 37±3.51 340.8±1.4
A6 43±2.0 36.6±1.1 83±2.00 198.3±2.8
A7 47.3±2.0 40±1.0 209±2.00 170.0±1.0
Values are expressed as mean± standard deviation
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3.6 pH of strips
The pH of FDSSs ranged from 5.4±0.10 to 6.1±0.05 (table 3). 
The pH was found to be acidic due to the presence of citric 
acid. As the observed pH values of strips were close to the 
buccal pH, the chances of irritation to the mucosal lining 
of oral cavity was negligible(7). The difference in pH values 
of the strips may be due to differences in excipients used in 
formulations.
3.7 Moisture absorption study
The moisture absorption study gives an idea about the 
stability of strips. The strip will be less stable if it has more 
absorption property. The results of moisture absorption 
study are given in the table 3.
It was observed that, the moisture absorption of the strip was 
increased with increase in the concentration of polymer as 
well as plasticizer. This may be due to hydrophilic nature of 
polymer and plasticizer.
3.8 Drug content
The drug content was found to be in between 93.1±1.49 to 
99.8±0.10 % (table 3) indicating uniform distribution of drug 
in the strips.
3.9 Disintegration time of strips
The disintegration time of FDSSs is shown in table 3. It 
was observed that increase in the polymer concentration 
increased the disintegration time of the strips. This may be 
due to the formation of viscous gel layer at high polymer 
concentration that prevents intimate contact between the 
particles of polymer. The mobility of drug particles in 
swollen matrices decreases thus increasing disintegration 
time(23). When PEG 400 concentration was increased, the 
disintegration time was found to be decreased which may be 
ascribed to its hydrophilic nature.
3.10 In Vitro Dissolution studies
Dissolution studies of FDSSs and marketed tablet 
formulation (MF) of rizatriptan benzoate was carried 
out using phosphate buffer pH 6.4. Figure 1 displays the 
drug release profile of FDSSs and MF. The FDSSs released 
nearly 75.2-100.2% drug within 6 minutes. Although, the 
difference in the release rate for formulations A1-A3, A6 
and A7 was insignificant, these formulations showed fast 
release as compared to the MF. As the concentration of 
polyox N-10 was increased from 4-12%, the amount of 
drug release was found to be decreased. This may be due 
to increase in the formation of viscous gel layer around the 
surface of strip that decreases the mobility of drug particles 
and reduces the release rate(23). The values of the MDT 
for FDSSs and MF are given in table 3. The release rate and 
MDT of formulations A1 and A2 was close to each other, 
however, the tensile strength of A2 was better. Therefore, 
formulation A2 was considered as an optimized FDSS.
Table 3. Evaluation of oral fast dissolving strips of rizatriptan benzoate
Formulations
Moisture absorption 
study
(n=3)
Disintegration time
(sec) (n=3)
pH Value
(n=3) Drug content (%)
Mean dissolution time 
(MDT)(min)
A1 2.43±0.14 6.0±0.05 6.0±0.05 97.3±1.48 0.52
A2 5.82±0.11 10.3±0.11 6.1±0.05 99.8±0.10 0.56
A3 10.29±1.14 13±0.05 5.9±0.10 95.5±0.92 0.64
A4 12.90±0.65 18 ±0.08 5.7±0.05 93.1±1.49 0.93
A5 15.38±0.14 61.3±0.05 5.4±0.10 94.8±0.70 1.23
A6 3.17±0.31 11.3±0.10 6.1 ±0.05 98.0±0.64 0.59
A7 7.51±0.20 9.0±0.15 6.0±0.10 93.1±1.49 0.61
MF - - - 0.74
Values are expressed as mean ± standard deviation
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Figure 1. Drug release profile of formulations A1 to A7 
and marketed formulation (MF)
3.11 Stability Studies
The stability study of optimized formulation A2 was carried 
out at 400C with 75% relative humidity for the period of 
three months. Table 4 shows the parameters of formulation 
A2 before and after the stability study. No significant change 
was noticed in the parameters of A2 after the stability study. 
The drug release profile A2 before and after the stability 
study is displayed in figure 2. The value of f2 after 90 days was 
found to be 80.98 whereas the difference factor (f1) value was 
found to be 2.44. This indicates that the release profile of the 
formulation A2 was not markedly affected by the changes in 
the temperature and humidity.
Table 4. In vitro parameters of batch A2 before and after 
stability study
Parameter Before stability 
study (n=3)
After stability study 
(n=3)
Weight of strip (mg) 45±1.0 46.33±0.85
Thickness of strip (µm) 33.3±0.57 33.9±0.51
Folding endurance 157±3.21 154±1.56
Tensile strength (kg/cm2) 186±3.2 182.5±2.80
Disintegration Time (sec) 10.3±0.11 10.8±1.08
Drug content (%) 99.8±0.1 99.1±0.42
Drug release at the end of 
2 min (%)
100.2±1.19 98.1±1.37
Values are expressed as mean ± standard deviation
Figure 2. Drug release profile of formulation A2 before 
and after stability study
3.12 Evaluation of taste
In the study of taste assessment of formulation A2, a panel of 
nine individuals was used and the volunteers were asked to 
assess the taste in general as well as taste in particular. Four 
criteria were used in assessing the taste: bitter, not bitter, 
slightly sweet, and sweet. It was observed that at 15th sec, the 
slight sweetness was sensed by most of the volunteers. The 
strip showed no bitterness up to 120sec. This makes it clear 
that efficient taste masking was achieved for FDSSs.
Table 4. Observations of taste masking of A2 after 
different time intervals
Volunteers
Taste level after
15sec 30sec 60sec 90sec 120sec
1 0 0 1 1 1
2 0 0 1 1 1
3 0 1 1 1 1
4 0 0 1 1 1
5 0 0 1 1 1
6 0 1 0 1 1
7 0 0 1 1 1
8 0 0 1 1 1
9 0 1 1 1 1
00- Sweet, 0-Slightly sweet, 1 –No bitterness and 2- Bitterness
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3.13 Compatibility study
The IR spectra of pure rizatriptan benzoate (Figure 3A), 
polyox N-10 (figure 3B) physical mixture of rizatriptan 
benzoate (figure 3C), and formulation A2 (figure 3D) are 
shown in figure 4. The IR spectrum of pure rizatriptan 
benzoate showed characteristic peaks at 725, 1379.40, 1565.59, 
1606.11 and 2881.62 cm-1, indicating rocking (medium 
stretching) of N-H in triazole, N-H bending in indole, C=N 
stretching in triazole, C=O stretching in aryl ester and C-H 
stretching respectively. These peaks were observed almost 
at the same wave number with the same intensity in the 
spectra of physical mixtures and formulation A2. Also, no 
extra peak was observed in IR spectrum of physical mixtures 
and formulations which indicate the absence of any potential 
physical or chemical interaction between the drug, polymer 
and other formulation additives. Thus, the formulation 
excipients were found to be compatible with the drug.
Figure 3. Overlay IR spectra of (A): Rizatriptan benzoate, 
(B): Polyox N-10 (C): Drug and Polyox N-10 (1:1) physical 
mixture, (D): Formulation A2
The supporting evidence for compatibility between drug and 
excipients was also obtained from DSC analysis (Figure 4). The 
DSC thermogram of rizatriptan benzoate (figure 4A) showed 
a sharp endothermic peak at 180.450 C which corresponds to 
the melting point of pure drug. DSC thermogram of physical 
mixture (figure 4B) and optimized formulation, A2 (figure 
4C) showed slight broad endothermic peak at 179.810 C and 
179.00C respectively. The DSC thermogram of formulation 
showed non-significant shift in endothermic peak of 
rizatriptan benzoate, along with reduction in peak height. 
This may be due to molecular dispersion of drug in polymer 
matrix. The absence of additional peaks in the thermogram 
of formulation indicates the lack of unusual interactions 
between drug and formulation excipients.
Figure 4. Overlay DSC thermograms (A) Rizatriptan 
benzoate, (B) Drug and Polyox N-10 (1:1) physical 
mixture, (C) Formulation A2
4. CONCLUSION
The FDSSs of rizatriptan benzoate were prepared using 
polyox N-10 as a strip forming materials by solvent casting 
method. Formulation variables like amount of polyox 
N-10, amount of plasticizer (PEG 400) were found to have 
influence on thickness, folding endurance, tensile strength, 
moisture absorption, in vitro disintegration time and in vitro 
dissolution of the strips. The FDSSs were found to be thin 
and showed fast disintegration, satisfactory dissolution and 
acceptable physico-mechanical characteristics. The bitter 
taste of rizatriptan benzoate could be successfully masked by 
using combination of sucralose and strawberry flavor. The 
stability study of strip A2 showed no significant (p<0.05) 
difference between in vitro drug release, disintegration time 
and physical properties of formulations.
Therefore, the FDSSs containing rizatriptan benzoate is 
considered to be potentially useful for treatment of migraine 
where improved patient compliance and convenience is 
expected.
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Migren tedavisi için tadı maskelenmiş oral rizatriptan 
benzoat hızlı çözünen dilaltı stripleri
ÖZ
Bu araştırmanın amacı, tadı maskelenmiş rizatriptan benzoat 
içeren hızlı çözünen dilaltı strip’inin geliştirilmesidir. Hızlı 
çözünen stripler (Fast Dissolving Strips =FDS) polimer ve 
plastikleştirici olarak sırasıyla Polyox N-10 and polietilenglikol 
400’ün (PEG 400) kullanıldığı çözücü dökme yöntemiyle 
hazırlanmışlardır. Hızlı çözünen striplerin pH’sı, katlanmaya 
karşı dayanıklılığı, gerilme kuvveti, nem absorbsiyonu, dağılması 
ve in vitro çözünmesi incelenmiştir. Tüm formülasyonlar 
baloncuk içermez ve yumuşak bir görünüş sergiler. Filmlerin 
pH’sı asidiktir. Polyox N-10 oranı arttıkça dağılma zamanının 
arttığı fakat serbestleşme hızının azaldığı gözlemlenmiştir. A2 
formülasyonu tüm değerlendirme sonuçlarını kabul edilebilir bir 
aralıkta göstermiştir ve optimize formül olarak düşünülmüştür. 
Optimize formülasyon tat maskeleme ve stabilite çalışmalarına 
tabi tutulmuştur. Tat maskeleme çalışmalarının sonuçları, ilacın 
acı tadının film içindeki tatlandırıcı ajanlar tarafından etkin bir 
şekilde maskelendiğini göstermiştir.
Anahtar kelimeler: Hızlı çözünen dilaltı stripleri, Polyox 
N-10, PEG 400, Rizatriptan benzoat
